Timber Hill LLC Reduces Stake in Thermo Fisher Scientific (TMO)

Timber Hill LLC lessened its position in Thermo Fisher Scientific (NYSE:TMO) by 72.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,619 shares of the medical research company’s stock after selling 22,522 shares during the period. Timber Hill LLC’s holdings in Thermo Fisher Scientific were worth $1,779,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Viking Global Investors LP bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $154,660,000. Cornerstone Investment Partners LLC raised its stake in shares of Thermo Fisher Scientific by 89.8% in the 4th quarter. Cornerstone Investment Partners LLC now owns 802,374 shares of the medical research company’s stock worth $152,355,000 after buying an additional 379,703 shares in the last quarter. Longview Partners Guernsey LTD raised its stake in shares of Thermo Fisher Scientific by 6.8% in the 4th quarter. Longview Partners Guernsey LTD now owns 4,876,890 shares of the medical research company’s stock worth $926,024,000 after buying an additional 311,977 shares in the last quarter. Elkfork Partners LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $46,978,000. Finally, Schroder Investment Management Group raised its stake in shares of Thermo Fisher Scientific by 28.1% in the 4th quarter. Schroder Investment Management Group now owns 1,103,685 shares of the medical research company’s stock worth $209,568,000 after buying an additional 242,062 shares in the last quarter. 86.52% of the stock is currently owned by institutional investors.

In other news, CEO Marc N. Casper sold 40,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the transaction, the chief executive officer now owns 334,622 shares in the company, valued at $70,324,159.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William G. Parrett sold 1,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $211.43, for a total value of $211,430.00. Following the transaction, the director now owns 11,660 shares in the company, valued at approximately $2,465,273.80. The disclosure for this sale can be found here. Insiders have sold 43,500 shares of company stock worth $9,129,330 in the last quarter. 0.49% of the stock is currently owned by corporate insiders.

Shares of Thermo Fisher Scientific opened at $214.94 on Friday, MarketBeat reports. Thermo Fisher Scientific has a 1-year low of $170.07 and a 1-year high of $226.44. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The firm has a market cap of $86.48 billion, a PE ratio of 21.71, a price-to-earnings-growth ratio of 1.58 and a beta of 1.14.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 25th. The medical research company reported $2.50 earnings per share for the quarter, beating analysts’ consensus estimates of $2.42 by $0.08. Thermo Fisher Scientific had a return on equity of 16.09% and a net margin of 10.24%. The business had revenue of $5.85 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the previous year, the company posted $2.08 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 22.8% compared to the same quarter last year. equities research analysts anticipate that Thermo Fisher Scientific will post 10.91 EPS for the current year.

A number of analysts have recently commented on the company. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Leerink Swann restated an “outperform” rating and issued a $239.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a report on Thursday, February 1st. They noted that the move was a valuation call. ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Barclays lifted their target price on Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Thermo Fisher Scientific has a consensus rating of “Buy” and an average target price of $224.38.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply